

UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF COLUMBIA

| | | |
|---|---|----------------------------------|
| WELLSTAT THERAPEUTICS CORPORATION |) | |
| 930 Clopper Road |) | |
| Gaithersburg, MD 20878 |) | |
| Plaintiff |) | |
| |) | |
| v. |) | Civil Case No. 1:09-cv-01866 |
| |) | |
| HON. DAVID KAPPOS |) | Assigned To: Friedman, Paul L. |
| Under Secretary of Commerce for |) | |
| Intellectual Property and |) | Assign Date: 9/30/2009 |
| Director of the United States Patent and |) | |
| Trademark Office |) | Description: Admn. Agency Review |
| Office of the General Counsel, |) | |
| United States Patent and Trademark Office |) | |
| P.O. Box 15667, Arlington, VA 22215 |) | |
| Madison Building East, Rm. 10B20 |) | |
| 600 Dulany Street, Alexandria, VA 22314 |) | |
| |) | |
| Defendant |) | |
| |) | |

Amended Complaint

Plaintiff, WELLSTAT THERAPEUTICS CORPORATION ("Wellstat"), for its amended complaint against the Honorable David Kappos, states as follows:

Nature of the action

1. This is an action by the assignee of United States Patent No. 7,514,555 B7 ("the '555 patent") seeking judgment, pursuant to 35 U.S.C. § 154(b)(4)(A), that the patent term adjustment for the '555 patent be changed from 82 days to at least 241 days.
2. This action arises under 35 U.S.C. § 154 and the Administrative Procedures Act, 5 U.S.C. §§ 701-706.

Jurisdiction and venue

3. This Court has jurisdiction to hear this action and is authorized to issue the relief sought pursuant to 28 U.S.C. §§ 1331, 1338(a), and 1361, 35 U.S.C. § 154(b)(4)(A) and 5 U.S.C. §§ 701-706.
4. Venue is proper in this district by virtue of 35 U.S.C. § 154(b)(4)(A).
5. This Complaint is timely filed in accordance with 35 U.S.C. § 154(b)(4)(A).

The parties

6. Plaintiff Wellstat is a corporation organized under the laws of Delaware, having a principal place of business at 930 Clopper Road, Gaithersburg, Maryland 20878.
7. Defendant David Kappos is the Under Secretary of Commerce for Intellectual Property and Director (“Director”) of the United States Patent and Trademark Office (“PTO”), acting in his official capacity. The Director is the head of the agency, charged by statute with providing management supervision for the PTO and for the issuance of patents. The Director is the official responsible for determining the period of patent term adjustment under 35 U.S.C. § 154.

Background

8. Kirvin L. Hodge, Shalini Sharma, Reid W. von Borstel, and Stephen D. Wolpe are the inventors of U.S. patent application number 10/531,618 (“the ‘618 application”) entitled “Compounds for the Treatment of Metabolic Disorders,” which was issued as the ‘555 patent on April 7, 2009. The ‘555 patent is attached as Exhibit A.
9. Plaintiff Wellstat is the assignee of the ‘555 patent, as evidenced by the assignment documents filed in the PTO.

10. Section 156 of title 35 of the United States Code requires that the Director of the PTO grant a patent term adjustment in accordance with the provisions of § 154(b). Specifically, 35 U.S.C. § 154(b)(3)(D) states that “[t]he Director shall proceed to grant the patent after completion of the Director’s determination of a patent term adjustment under the procedures established under this subsection, notwithstanding any appeal taken by the applicant of such determination.”

11. In determining patent term adjustment, the Director is required to extend the term of a patent for a period equal to the total number of days attributable to delay by the PTO under 35 U.S.C. § 154(b)(1)(A), (B), and (C), as limited by any overlapping periods of delay by the PTO as specified under 35 U.S.C. 154(b)(2)(A), any disclaimer of patent term by the applicant under 35 U.S.C. § 154(b)(2)(B), and any delay attributable to the applicant under 35 U.S.C. § 154(b)(2)(C).

12. The Director made a determination of patent term adjustment pursuant to 35 U.S.C § 154(b)(3) and issued the ‘555 patent reflecting that determination.

13. 35 U.S.C. § 154(b)(4)(A) provides that “[a]n applicant dissatisfied with a determination made by the Director under paragraph (3) shall have remedy by a civil action against the Director filed in the United States District Court for the District of Columbia within 180 days after grant of the patent. Chapter 7 of title 5 shall apply to such action.”

14. On June 3, 2009, in accordance with 37 CFR 1.705(d), Wellstat filed a Request for Reconsideration of Patent Term Adjustment with the PTO to correct errors in the Director’s determination. On September 28, 2009, The PTO mailed its Decision on Request for Reconsideration of Patent Term Adjustment [attached as Exhibit C] dismissing Wellstat’s Request. This Decision was delivered to Wellstat the same day the original Complaint in this

action was filed (September 30, 2009). The existence of the Decision of September 30, 2009 was unknown to Wellstat's attorneys until after the Complaint was filed. This Amended Complaint is being filed to include this new information.

Claim for relief

15. The allegations of paragraphs 1-14 are incorporated in this claim for relief as if fully set forth.

16. The patent term adjustment for the '555 patent, as determined by the Director under 35 U.S.C. § 154(b) and indicated on the face of the '555 patent, is 82 days. (See Ex. A at 1.) The determination of this 82 day patent term adjustment is in error because the PTO failed to properly account for delays that occurred pursuant to both 35 U.S.C. § 154(b)(1)(A) and 35 U.S.C. § 154(b)(1)(B), to the extent such delays did not occur on the same days. The correct patent term adjustment for the '555 patent is at least 241 days.

17. The '618 application commenced and entered national stage under 35 USC Section 371 (c) (1), (2) and (4) on April 14, 2005, and the '618 application issued as the '555 patent on April 7, 2009.

18. Under 35 U.S.C. § 154(b)(1)(A), the number of days attributable to PTO examination delay ("A Delay") is 159 days.

19. Under 35 U.S.C. § 154(b)(1)(B), the number of days attributable to application pendency in excess of three years ("B Delay") is 358 days.

20. Under 35 U.S.C. § 154(b)(2)(C), the number of days of applicant delay is 276 days.

21. 35 U.S.C. § 154(b)(2)(A) provides that "[t]o the extent that periods of delay attributable to grounds specified in paragraph (1) overlap, the period of any adjustment... shall not exceed the actual number of days the issuance of the patent was delayed." The overlap between the "A

Delay" period of time and the "B Delay" period in the prosecution of the '555 patent is zero days.

22. The '555 patent is not subject to a disclaimer of term. Thus the period of patent term adjustment is not limited under 35 U.S.C. § 154(b)(2)(B).

23. Accordingly, the correct patent term adjustment under 35 U.S.C. § 154(b)(1) and (2) is the sum of the "A Delay" and "B Delay" ($159 + 358 = 517$ days), reduced by the number of days of overlap of "A Delay" and "B Delay" (0 Days) and applicant delay (276 days), for a net adjustment of 241 days.

24. The Director erred in the determination of patent term adjustment by treating the entire period of "A Delay," and not only the period of "A Delay" that occurred on the same calendar days as "B Delay," as the period of overlap between the "A Delay" and the "B Delay." Thus, the Director erroneously arrived at a net patent term adjustment of 82 days.

25. In *Wyeth v. Dudas*, 580 F.Supp.2d 138 (D.D.C. 2008), this Court explained the proper construction of the provisions of 35 U.S.C. § 154(b) for determining patent term adjustment. In accordance with *Wyeth*, the patent term adjustment for the '555 patent is properly determined to be 241 days, as set forth above. A copy of the *Wyeth* ruling is attached as Exhibit B.

26. The Director's determination that the '555 patent is entitled to only 82 days of patent term adjustment is arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with the law and in excess of statutory jurisdiction, authority, or limitation.


Prayer for relief

Wherefore, Plaintiff demands judgment against Defendant and respectfully requests that this Court enter Orders:

- A. Changing the period of patent term adjustment for the '555 patent term from 82 days to 241 days and requiring the Director to extend the term of the '555 patent to reflect the 241 day patent term adjustment.
- B. Granting such further relief as the nature of the case may admit or require and as may be just and equitable.

October 5, 2009

Respectfully submitted,



Robert A. Rowan (Bar No. 391630)
NIXON & VANDERHYE P.C.
901 North Glebe Road
11th Floor
Arlington, Virginia 22203
Phone: 703-816-4007
Fax: 703-816-4100

Attorney for Plaintiff
WELLSTAT THERAPEUTICS CORPORATION

Exhibit A

Civil Case No. 1:09-cv-01866-PLF



US007514555B2

(12) **United States Patent**
Hodge et al.

(10) **Patent No.:** US 7,514,555 B2
(45) **Date of Patent:** Apr. 7, 2009

(54) **COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS**

2003/0149107 A1 8/2003 Sharma et al.
2005/0090555 A1 4/2005 Sharma et al.
2005/0256333 A1 11/2005 Sharma et al.

(75) Inventors: **Kirvin L. Hodge, Laurel, MD (US); Shalini Sharma, Gaithersburg, MD (US); Reid W. von Borstel, Potomac, MD (US); Stephen D. Wolpe, Boyds, MD (US)**

FOREIGN PATENT DOCUMENTS

| | | |
|----|----------------|---------|
| WO | WO02/100341 | 12/2002 |
| WO | 2004/041165 A2 | 5/2004 |
| WO | 2006/127133 A2 | 5/2004 |
| WO | WO2004/073611 | 9/2004 |

(73) Assignee: **Wellstat Therapeutics Corporation, Gaithersburg, MD (US)**

OTHER PUBLICATIONS

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 82 days.

(21) Appl. No.: **10/531,618**

(22) PCT Filed: **Apr. 8, 2004**

(86) PCT No.: **PCT/US2004/010799**

§ 371 (c)(1),
(2), (4) Date: **Apr. 14, 2005**

(87) PCT Pub. No.: **WO2004/091486**

PCT Pub. Date: **Oct. 28, 2004**

(65) **Prior Publication Data**

US 2006/0014784 A1 Jan. 19, 2006

Related U.S. Application Data

(60) Provisional application No. 60/462,960, filed on Apr. 15, 2003.

(51) **Int. Cl.**

C07D 213/00 (2006.01)
C07D 211/70 (2006.01)
C07C 69/76 (2006.01)
C07C 229/00 (2006.01)
A61K 31/47 (2006.01)

(52) **U.S. Cl.** 546/1; 546/329; 560/8; 560/19; 560/39; 560/75; 514/310; 514/866

(58) **Field of Classification Search** 514/310
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,219,579 A * 6/1993 Tisdale et al. 424/573
5,604,225 A * 2/1997 Reiffen et al. 514/230.8
5,665,387 A * 9/1997 Mathieu et al. 424/464
6,143,787 A 11/2000 Moinet et al.
6,156,781 A * 12/2000 Talley et al. 514/406
6,307,080 B1 * 10/2001 Pischel et al. 556/131
6,858,602 B2 2/2005 Sharma et al.
6,916,848 B2 7/2005 Sharma
6,924,314 B2 8/2005 Sharma et al.
6,946,491 B2 9/2005 Sharma et al.
7,012,071 B2 3/2006 Sharma et al.
7,041,659 B2 5/2006 Sharma
7,045,541 B2 5/2006 Sharma et al.
7,101,910 B2 9/2006 Sharma
2002/0028943 A1 * 3/2002 Griffin 546/223

Younis, et al., "The prevention of type 2 diabetes mellitus: recent advances", QJ Med., vol. 97, pp. 451-455, 2004.
Goff, et al., "Prevention of Cardiovascular Disease in Persons with type 2 diabetes Mellitus: Current Knowledge and Rational for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial", AM J Cardiol., 99(12A): S4-S20, 2007. (Abstract).

Knowler, et al., "Perspectives in Diabetes: Preventing Non-Insulin-Dependent Diabetes", Diabetes, vol. 44, pp. 483-488, 1995.
Friedman, et al., "Impaired Glucose Transport and Insulin Receptor Tyrosine Phosphorylation in Skeletal Muscle From Obese Women with Gestational Diabetes", Diabetes, vol. 48, pp. 1807-1814, Sep. 1999.

Kilpatrick, et al. "Insulin Resistance, the Metabolic Syndrome, and Complication Risk in Type 1 Diabetes", Diabetes Care, vol. 30, No. 3, pp. 707-712, Mar. 2007.

(Continued)


Primary Examiner—Kevin E Weddington

(74) **Attorney, Agent, or Firm**—Lewis J. Kreisler

(57) **ABSTRACT**

Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Wherein n is 1 or 2; m is 0, 1, 2, 3 or 4; q is 0 or 1; t is 0 or 1; R² is alkyl having from 1 to 3 carbon atoms; R³ is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and R¹ is hydrogen or alkyl having 1 or 2 carbon atoms, provided that when m is 0 or 1, R¹ is not hydrogen. Alternatively, when R¹ is hydrogen, the biologically active agent can be a pharmaceutically acceptable salt of the compound of Formula I.

(I)



US 7,514,555 B2

Page 2

OTHER PUBLICATIONS

Pending (as of Mar. 26, 2007) claims from U.S. Appl. No. 10/566,302.

Pending (as of Mar. 26, 2007) claims from U.S. Appl. No. 10/553,936.

Pending (as of Mar. 26, 2007) claims from U.S. Appl. No. 10/554,586.

Pending (as of Mar. 26, 2007) claims from U.S. Appl. No. 11/535,779.

Child, et al., "Fenbufen, a New Anti-Inflammatory Analgesic: Synthesis and Structure-Activity Relationships of Analogs", Journal of Pharmaceutical Sciences, 1977, 66(4), pp. 466-476.

Connolly, et al., "Design and Synthesis of a Novel and Potent Series of Inhibitors of Cytosolic Phospholipase A2 Based on a 1,3-Disubstituted Propan-2-one Skeleton", Journal of Medicinal Chemistry, 2002, 45(6), pp. 1348-1362.

Flynn, et al., "One-Pot Synthesis of Benzofuran and Indole Inhibitors of Tubulin Polymerization", Journal of Medicinal Chemistry, 2002, 45(12), pp. 2670-2673.

Argiles, et al., "Journey from cachexia to obesity by TNF", The FASEB Journal, 1997, 11(10), pp. 743-751. (Abstract).

de Alvaro, et al., "Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner", J. Biol. Chem., 2004, 279(17), pp. 17070-17078. (Abstract).

Rose, et al., "Altered insulin response to glucose in weight-losing cancer patients", Anticancer Research, 1994, 14(2B); pp. 647-650. (Abstract).

Tayek, "A review of cancer cachexia and abnormal glucose metabolism in humans with cancer", Journal of the American College of Nutrition, 1992, 11(4), pp. 445-456. (Abstract).

Wedick, et al., "Insulin resistance precedes weight loss in adults without diabetes: the Rancho Bernardo Study", American Journal of Epidemiology, 2001, 153(12), pp. 1199-1205. (Abstract).

Pending (as of Dec. 18, 2006) claims from U.S. Appl. No. 10/532,690.

* cited by examiner

US 7,514,555 B2

1

COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS

REFERENCE TO PRIOR APPLICATIONS

This is the national phase under 35 U.S.C. §371 of International Application No. PCT/US2004/010799, having an international filing date of Apr. 8, 2004. This application claims priority of U.S. Provisional Application No. 60/462, 960, filed Apr. 15, 2003, the contents of which are hereby incorporated by reference.

BACKGROUND OF THE INVENTION

Diabetes mellitus is a major cause of morbidity and mortality. Chronically elevated blood glucose leads to debilitating complications: nephropathy, often necessitating dialysis or renal transplant; peripheral neuropathy; retinopathy leading to blindness; ulceration of the legs and feet, leading to amputation; fatty liver disease, sometimes progressing to cirrhosis; and vulnerability to coronary artery disease and myocardial infarction. There are two primary types of diabetes. Type I, or insulin-dependent diabetes mellitus (IDDM) is due to autoimmune destruction of insulin-producing beta cells in the pancreatic islets. The onset of this disease is usually in childhood or adolescence. Treatment consists primarily of multiple daily injections of insulin, combined with frequent testing of blood glucose levels to guide adjustment of insulin doses, because excess insulin can cause hypoglycemia and consequent impairment of brain and other functions.

Type II, or noninsulin-dependent diabetes mellitus (NIDDM) typically develops in adulthood. NIDDM is associated with resistance of glucose-utilizing tissues like adipose tissue, muscle, and liver, to the actions of insulin. Initially, the pancreatic islet beta cells compensate by secreting excess insulin. Eventual islet failure results in decompensation and chronic hyperglycemia. Conversely, moderate islet insufficiency can precede or coincide with peripheral insulin resistance. There are several classes of drugs that are useful for treatment of NIDDM: 1) insulin releasers, which directly stimulate insulin release, carrying the risk of hypoglycemia; 2) prandial insulin releasers, which potentiate glucose-induced insulin secretion, and must be taken before each meal; 3) biguanides, including metformin, which attenuate hepatic gluconeogenesis (which is paradoxically elevated in diabetes); 4) insulin sensitizers, for example the thiazolidinedione derivatives rosiglitazone and pioglitazone, which improve peripheral responsiveness to insulin, but which have side effects like weight gain, edema, and occasional liver toxicity; 5) insulin injections, which are often necessary in the later stages of NIDDM when the islets have failed under chronic hyperstimulation.

Insulin resistance can also occur without marked hyperglycemia, and is generally associated with atherosclerosis, obesity, hyperlipidemia, and essential hypertension. This cluster of abnormalities constitutes the "metabolic syndrome" or "insulin resistance syndrome". Insulin resistance is also associated with fatty liver, which can progress to chronic inflammation (NASH; "nonalcoholic steatohepatitis"), fibrosis, and cirrhosis. Cumulatively, insulin resistance syndromes, including but not limited to diabetes, underlie many of the major causes of morbidity and death of people over age 40.

Despite the existence of such drugs, diabetes remains a major and growing public health problem. Late stage complications of diabetes consume a large proportion of national health care resources. There is a need for new orally active

2

therapeutic agents which effectively address the primary defects of insulin resistance and islet failure with fewer or milder side effects than existing drugs.

Currently there are no safe and effective treatments for fatty liver disease. Therefore such a treatment would be of value in treating this condition.

WO 02/100341 (Wellstat Therapeutics Corp.) discloses certain compounds substituted by hydrogen or an oxo group at the final position of the acid, for example 4-(3-(2,6-Dimethylbenzyloxy)phenyl)-butyric acid and 4-(3-(2,6-Dimethylbenzyloxy)phenyl)-4-oxobutyric acid. WO 02/100341 does not disclose any compounds within the scope of Formula I shown below, in which the final position of the acid is hydroxy-substituted.


15

SUMMARY OF THE INVENTION

This invention provides a biologically active agent as described below. This invention provides the use of the biologically active agent described below in the manufacture of a medicament for the treatment of insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis or arteriosclerosis. This invention provides methods of treating a mammalian subject with insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis or arteriosclerosis comprising administering to the subject an effective amount of the biologically active agent described below. This invention provides a pharmaceutical composition comprising the biologically active agent described below and a pharmaceutically acceptable carrier.

The biologically active agent in accordance with this invention is a compound of Formula I:

Formula I



wherein n is 1 or 2; m is 0, 1, 2, 3 or 4; q is 0 or 1; t is 0 or 1; R² is alkyl having from 1 to 3 carbon atoms; R³ is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms;

A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and R¹ is hydrogen or alkyl having 1 or 2 carbon atoms, provided that when m is 0 or 1, R¹ is not hydrogen. Alternatively, when R¹ is hydrogen, the biologically active agent can be a pharmaceutically acceptable salt of the compound of Formula I.

US 7,514,555 B2

3

The biologically active agents described above have activity in one or more of the biological activity assays described below, which are established animal models of human diabetes and insulin resistance syndrome. Therefore such agents would be useful in the treatment of diabetes and insulin resistance syndrome. All of the exemplified compounds that were tested demonstrated activity in at least one of the biological activity assays in which they were tested.

DETAILED DESCRIPTION OF THE INVENTION

Definitions

As used herein the term "alkyl" means a linear or branched-chain alkyl group. An alkyl group identified as having a certain number of carbon atoms means any alkyl group having the specified number of carbons. For example, an alkyl having three carbon atoms can be propyl or isopropyl; and alkyl having four carbon atoms can be n-butyl, 1-methylpropyl, 2-methylpropyl or t-butyl.

As used herein the term "halo" refers to one or more of fluoro, chloro, bromo, and iodo.

As used herein the term "perfluoro" as in perfluoromethyl or perfluoromethoxy, means that the group in question has fluorine atoms in place of all of the hydrogen atoms.

As used herein "Ac" refers to the group $\text{CH}_3\text{C}(\text{O})-$.

Certain chemical compounds are referred to herein by their chemical name or by the two-letter code shown below. Compound CR is included within the scope of Formula I shown above.

BI 4-(3-(2,6-Dimethylbenzyloxy)-phenyl)-4-oxobutanoic acid

CR 4-(3-(2,6-Dimethylbenzyloxy)-phenyl)-4(R)-hydroxybutanoic acid

As used herein the transitional term "comprising" is open-ended. A claim utilizing this term can contain elements in addition to those recited in such claim.

COMPOUNDS OF THE INVENTION

The asterisk in the depiction of Formula I above indicates a chiral center. This invention provides the racemate, the (R) enantiomer, and the (S) enantiomer, of the compounds of Formula I, all of which are active. Mixtures of these enantiomers can be separated by using HPLC, for example as described in Chirality 11:420-425 (1999).

In an embodiment of the agent, use, method or pharmaceutical composition described above, n is 1; q is 0; t is 0; R³ is hydrogen; and A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy. In a more specific embodiment, A is 2,6-dimethylphenyl. Examples of such compounds include Compound CR.


In a preferred embodiment of the biologically active agent of this invention, the agent is in substantially (at least 98%) pure form.

Reaction Schemes

The biologically active agents of the present invention can be made in accordance with the following reaction schemes.

The compound of formula I where m is 2 to 4, q is 0, t is 0 or 1, and n is 1 or 2, R³ is hydrogen, halo, alkoxy having from 1 to 3 carbon atoms or alkyl having from 1 to 3 carbon atoms, and R¹ is hydrogen or alkyl having from 1 to 2 carbon atoms, i.e. compounds of formula:

4



5

10

wherein A is described as above, can be prepared via reaction of scheme 1.

In the reaction scheme of Scheme 1, A, t, n, R³ and R¹ are as above. Y is a leaving group and p is 1 to 3. The compound of formula II is converted to the compound of formula V via reaction of step (a) using Mitsunobu condensation of II with III using triphenylphosphine and diethyl azodicarboxylate or diisopropyl azodicarboxylate. The reaction is carried out in a suitable solvent for example tetrahydrofuran. Any of the conditions conventionally used in Mitsunobu reactions can be utilized to carry out the reaction of step (a).

The compound of formula V can also be prepared by etherifying or alkylating the compound of formula II with a compound of formula IV via the reaction of step (b) by using suitable base such as potassium carbonate, sodium hydride, triethylamine, pyridine and the like. In the compound of formula IV, Y, include but are not limited to mesyloxy, tosyloxy, chloro, bromo, iodo, and the like. Any conventional conditions to alkylate a hydroxyl group with a leaving group can be utilized to carry out the reaction of step (b). The reaction of step (b) is preferred over step (a) if compound of formula IV is readily available.

The compound of formula V is converted to the compound of formula VII via reaction of step (c) by alkylating the compound of formula V with the compound of formula VI. This reaction is carried out in the presence of approximately a molar equivalent of a conventional base that converts acetophenone to 3-keto ester (i.e. gamma-keto ester). In carrying out this reaction it is generally preferred but not limited to utilize alkali metal salts of hexamethyldisilane such as lithium bis(trimethylsilyl) amide and the like. Generally this reaction is carried out in inert solvents such as tetrahydrofuran: 1,3-Dimethyl-3,4,5,6-tetrahydro-2 (1H)-pyrimidinone. Generally the reaction is carried out at temperatures of from -65° C. to 25° C. Any of the conditions conventional in such alkylation reactions can be utilized to carry out the reaction of step (c).

The compound of formula VII is converted to the compound of VIII via reaction of step (d) by reducing the ketone group to an alcohol group. The reaction is carried out by utilizing a conventional reducing agent that converts ketone to alcohol. In carrying out this reaction it is generally preferred but not limited to utilize sodium borohydride as the reducing agent. Generally this reaction is carried out in solvents such as methanol, ethanol and the like. Generally the reaction is carried out at temperatures of from 0° C. to 25° C. The product can be isolated and purified by techniques such as extraction, evaporation, chromatography, and recrystallization. Racemic mixtures of formula VIII can be separated by using HPLC. (Chirality 11:420-425 (1999)).

The compound of formula VIII is the compound of formula I where R¹ is an alkyl group having from 1 to 2 carbon atoms.


The compound of formula VIII can be converted to the compound of formula I where R¹ is H by ester hydrolysis. Any conventional method of ester hydrolysis will produce the compound of formula I where R¹ is H.

US 7,514,555 B2


5

6

Reaction Scheme 1



The compound of formula I where m is 2 to 4, q is 1, t is 0 or 1, and n is 1 or 2, R^3 is hydrogen, halo, alkoxy having from 1 to 3 carbon atoms or alkyl having from 1 to 3 carbon atoms, R^2 is alkyl having from 1 to 3 carbon atoms and R^1 is hydrogen or alkyl having from 1 to 2 carbon atoms, i.e. compounds of formula:



wherein A is described as above, can be prepared via reaction of scheme 2.

In the reaction scheme of Scheme 2, A , t , n , R^3 and R^2 are as above. Y is chloro or bromo and p is 1 to 3.

The compound of formula IX can be mesylated to furnish the compound of formula X via reaction of step (e). Any conventional conditions to carry out the mesylation reaction of a hydroxyl group can be utilized to carry out the step (e). The compound of formula X is then heated with the compound of formula XI to produce the compound of formula

40 XII. Any of the conditions conventional to produce amino alcohol can be utilized to carry out the reaction of step (f).

In the compound of formula XII, alcohol can be displaced by chloro or bromo by treating the compound of formula XII with thionyl chloride, bromine, phosphorus tribromide and the like to produce the compound of formula XIII. Any conventional method to displace alcohol with chloro or bromo can be utilized to carry out the reaction of step (g).

45 The compound of formula XIII can be reacted with the compound of formula II via reaction of step (h) in the presence of a suitable base such as potassium carbonate, sodium hydride, triethylamine and the like. The reaction is carried out in conventional solvents such as dimethylformamide, tetrahydrofuran and the like to produce the corresponding compound of formula XIV. Any conventional method of etherification of a hydroxyl group in the presence of base (preferred base being potassium carbonate) can be utilized to carry out the reaction of step (h).

50 The compound of formula XIV can be converted to the compound of formula XV via reaction of step (i) by alkylating the compound of formula XIV with the compound of formula VI. This reaction is carried out in the presence of approximately a molar equivalent of a suitable base such as lithium hexamethyldisilane. This reaction is carried out in the same manner as described in connection with the reaction of step (c) of Scheme

55 The compound of formula XV can be converted to the compound of XVI via reaction of step (j) by reducing the

US 7,514,555 B2

7

ketone group to an alcohol group. The reaction is carried out by utilizing a conventional reducing agent that converts ketone to alcohol. In carrying out this reaction it is generally preferred but not limited to utilize sodium borohydride as the reducing agent. Generally this reaction is carried out in solvents such as methanol, ethanol or the like. Generally the reaction is carried out at temperatures of from 0° C. to 25° C. The product can be isolated and purified by techniques such as extraction, evaporation, chromatography, and recrystallization.

Racemic mixtures of formula XVI can be separated by using HPLC. (Chirality 11:420-425 (1999)

The compound of formula XVI is the compound of formula I where R¹ is alkyl having from 1 to 2 carbon atoms.

The compound of formula XVI can be converted to the free acid by ester hydrolysis. Any conventional method of ester hydrolysis will produce the compound of formula I where R¹ is H.


5

10

15

8


R² is alkyl having from 1 to 3 carbon atoms and R¹ is alkyl having from 1 to 2 carbon atoms, i.e. compounds of formula:



wherein A is described as above, can be prepared via reaction of scheme 3.

In the reaction scheme of Scheme 3, A, t, n, R³ and R² are as above. R¹ is an alkyl group having from 1 to 2 carbon atoms.

Reaction Scheme 2



The compound of formula I where m is 1, q is 0 or 1, t is 0 or 1; and n is 1 or 2, R³ is hydrogen, halo, alkoxy having from 1 to 3 carbon atoms or alkyl having from 1 to 3 carbon atoms,

65 The compound of formula V (prepared in the same manner as described in the reaction of scheme 1) or XIV (prepared in the same manner as described in the reaction of scheme 2) can

US 7,514,555 B2


9

be reacted with dialkyl carbonate via reaction of step (k) in the presence of a suitable base such as sodium hydride and the like. The reaction can be carried out in conventional solvents such as N,N-dimethylformamide, tetrahydrofuran, dichloromethane and the like followed by addition of dialkyl carbonate such as dimethyl or diethyl carbonate to produce the corresponding compound of formula XVII. Any conditions conventional in such alkylation reactions can be utilized to carry out the reaction of step (k).

The compound of formula XVII can be converted to the compound of formula XVIII via reaction of step (l) by reducing the beta-keto group to an alcohol group. The reaction can be carried out by utilizing a conventional reducing agent that converts ketone to alcohol. The reaction can be carried out by hydrogenation using a Raney nickel catalyst that had been treated with tartaric acid (Harada, T.; Izumi, Y. Chem Lett. 1978, 1195-1196) or hydrogenation with a chiral homogeneous ruthenium catalyst (Akutagawa, S.; Kitamura, M.; Kumobayashi, H.; Noyori, R.; Ohkuma, T.; Sayo, N.; Takaya, M. J. Am. Chem. Soc. 1987, 109, 5856-5858). The reduction can also be carried out by using sodium borohydride and the like. Generally this reaction is carried out in solvents such as methanol, ethanol and the like. Generally the reaction is carried out at temperatures of from 0° C. to 25° C. The product can be isolated and purified by techniques such as extraction, evaporation, chromatography, and recrystallization. Racemic mixtures of formula XVIII can be separated by using HPLC. (Chirality 11:420-425 (1999))


The compound of formula XVIII is the compound of formula I where m is 1 and R¹ is alkyl having from 1 to 2 carbon atoms.

Reaction Scheme 3



The compound of formula I where m is 0, q is 0 or 1, t is 0 or 1, and n is 1 or 2, R³ is hydrogen, halo, alkoxy having from 1 to 3 carbon atoms or alkyl having from 1 to 3 carbon atoms, and R¹ is hydrogen or alkyl having from 1 to 2 carbon atoms, R² is alkyl having from 1 to 3 carbon atoms i.e. compounds of formula:

10



wherein A is described as above, can be prepared via reaction of scheme 4.

In the reaction of Scheme 4, t, n, A, R², R³ and R¹ are as above.


The compound of formula V (prepared in the same manner as described in the reaction of scheme 1) or the compound of formula XVI (prepared in the same manner as described in the reaction of scheme 2) can be converted to the compound of formula XIX via reaction of step (m) by oxidation of methyl group with selenium dioxide in the presence of pyridine. Generally the reaction is carried out at temperatures of from 25° C.-100° C. The product can be isolated and purified by techniques such as extraction, evaporation, chromatography, and recrystallization.

The compound of formula XIX can be converted to compound of formula XX via reaction of step (n) by hydrogenation of alpha-keto acid using catalyst for example rhodium-{amidophosphine-phosphinite} (Tetrahedron: Asymmetry, Vol 8, No. 7, 1083-1099, 1997), [Ru₂Cl₄(BINAP)₂](NEt₃) (EP-A-0 295 890) and the like. Any conditions conventional in such hydrogenations can be utilized to carry out the reaction of step (n). Racemic mixtures of formula XX can be separated by using HPLC. (Chirality 11:420425 (1999)).

The compound of formula XX is the compound of formula I where m is 0 and R¹ is H.

The compound of formula XX can be converted to compound of formula I where R¹ is alkyl having from 1 to 2 carbon atoms by esterification using methanol or ethanol. The reaction can be carried out either by using catalysts for example H₂SO₄, TsOH and the like or by using dehydrating agents for example dicyclohexylcarbodiimide and the like. Generally the reaction is carried out in solvents such as N,N-dimethylformamide, tetrahydrofuran, dichloromethane or the like. Generally the reaction is carried out at temperatures of from 0° C. to 100° C. The product can be isolated and purified by techniques such as extraction, evaporation, chromatography, and recrystallization.


Reaction Scheme 4




US 7,514,555 B2

11


-continued




(n) →



The compound of formula I where m is 0, q is 0 or 1, t is 0 or 1, and n is 1 or 2, R³ is hydrogen, halo, alkoxy having from 1 to 3 carbon atoms or alkyl having from 1 to 3 carbon atoms, and R¹ is hydrogen or alkyl having from 1 to 2 carbon atoms, R² is alkyl having from 1 to 3 carbon atoms i.e. compounds of formula:



can also be prepared from the compound of formula XXI,



wherein R³ is hydrogen, halo, alkoxy having from 1 to 3 carbon atoms or alkyl having from 1 to 3 carbon atoms via reaction of scheme 5.

In the reaction of Scheme 5, t, n, A, R², R³ and R¹ are as above. Y is chloro or bromo.

The compound of formula XXI can be converted to compound of formula XXII via reaction of step (O) by reaction with compound of formula III or with the compound of formula IV (prepared in the same manner as described in the reaction of scheme 1) or with the compound of formula XIII (prepared in the same manner as described in the reaction of scheme 2). These reactions can be carried out in the same manner as described in connection with reaction steps of (a), (b) or (h). The compound of formula XXII can be converted to the compound of formula XXIII via reaction of step (p) by reaction with NaCN or KCN in the presence of NaHSO₃ and

12

water followed by hydrolysis to give compound of formula XXIII. (Organic Syntheses; Wiley: New York, 1941; Collect. Vol. 1, p 336.)


The compound of formula XXII can be converted directly to the compound of formula XXIII via reaction of step (q) by reaction in the presence of a suitable catalyst for example triethylbenzylammonium chloride and the like. Generally the reaction is carried out in solvents such as chloroform-aq sodium hydroxide. Generally the reaction is carried out at temperatures of from 25° C. to 100° C. (Synthesis 1974, 724-725) Racemic mixtures of formula XXIII can be separated by using HPLC. (Chirality 11:420-425 (1999)

The compound of formula XXIII is the compound of formula I where m is 0 and R¹ is H.


The compound of formula XXIII can be converted to compound of formula I where R¹ is alkyl having from 1 to 2 carbon atoms by esterification using methanol or ethanol. The reaction can be carried out either by using catalysts for example H₂SO₄, TsOH and the like or by using dehydrating agents for example dicyclohexylcarbodiimide and the like. Generally the reaction is carried out in solvents such as N, N'-dimethylformamide, tetrahydrofuran, dichloromethane or the like. Generally the reaction is carried out at temperatures of from 0° C. to 100° C. The product can be isolated and purified by techniques such as extraction, evaporation, chromatography, and recrystallization.

30


Reaction Scheme 5



The compound of formula III,



and the compound of formula IV, where t is 0 or 1, n is 1 or 2, i.e. compounds of formula:



US 7,514,555 B2

13

wherein A is described as above, and Y is a leaving group, can be prepared via reaction of scheme 6.

In the reaction of Scheme 6, A is described as above and Y is a leaving group. The compound of formula XXIV can be reduced to the compound of formula XXV via reaction of step (r). The reaction is carried out utilizing a conventional reducing agent for example alkali metal hydride such as lithium aluminum hydride. The reaction is carried out in a suitable solvent, such as tetrahydrofuran. Any of the conditions conventional in such reduction reactions can be utilized to carry out the reaction of step (r).

The compound of formula XXV is the compound of formula III where t is 0 and n is 1.

The compound of formula XXV can be converted to the compound of formula XXVI by displacing hydroxyl group with a halogen group preferred halogen being bromo or chloro. Appropriate halogenating reagents include but are not limited to thionyl chloride, bromine, phosphorous tribromide, carbon tetrabromide and the like. Any conditions conventional in such halogenation reactions can be utilized to carry out the reaction of step (s).

The compound of formula XXVI is the compound of formula IV where t is 0 and n is 1.

The compound of formula XXVI can be converted to the compound of formula XXVII by reacting XXVI with an alkali metal cyanide for example sodium or potassium cyanide. The reaction is carried out in a suitable solvent, such as dimethyl sulfoxide. Any of the conditions conventionally used in the preparation of nitrile can be utilized to carry out the reaction of step (t).

The compound of formula XXVII can be converted to the compound of formula XXVIII via reaction step (u) by acid or base hydrolysis. In carrying out this reaction it is generally preferred to utilize basic hydrolysis, for example aqueous sodium hydroxide. Any of the conditions conventionally used in hydrolysis of nitrile can be utilized to carry out the reaction of step (u).

14

The compound of formula XXVIII can be reduced to give the compound of formula XXIX via reaction of step (v). This reaction can be carried out in the same manner as described hereinbefore in the reaction of step (r).

The compound of formula XXIX is the compound of formula III where t is 1 and n is 1.

The compound of formula XXIX can be converted to the compound of formula XXX via reaction of step (w) in the same manner as described hereinbefore in connection with the reaction of step (s).

The compound of formula XXX is the compound of formula IV where t is 1 and n is 1.

The compound of formula XXX can be reacted with diethyl malonate utilizing a suitable base for example sodium hydride to give compound of formula XXXI. The reaction is carried out in suitable solvents, such as dimethylformamide, tetrahydrofuran and the like. Any of the conditions conventional in such alkylation reactions can be utilized to carry out the reaction of step (x).

The compound of formula XXXI can be hydrolyzed by acid or base to give compound of formula XXXII via reaction of step (y).


The compound of formula XXXII can be converted to the compound of formula XXXIII via reaction of step (z) in the same manner as described hereinbefore in connection with the reaction of step (r).

The compound of formula XXXIII is the compound of formula III where t is 1 and n is 2.

The compound of formula XXXIII can be converted to the compound of formula XXXIV via reaction of step (a') in the same manner as described hereinbefore in connection with the reaction of step (s).

The compound of formula XXXIV is the compound of formula IV where t is 1 and n is 2.


Reaction Scheme 6



US 7,514,555 B2

15

The compound of formula II where R³ is halo, alkoxy having from 1 to 3 carbon atoms or 6 alkyl having from 1 to 3 carbon atoms, i.e. compounds of formula:



can be prepared via reaction of scheme 7.


In the reaction of Scheme 7, R¹ is H and R³ is halo, alkoxy having from 1 to 3 carbon atoms or alkyl having from 1 to 3 carbon atoms.

The compound of formula II can be synthesized according to the method of George M Rubottom et al., J. Org. Chem. 1983, 48, 1550-1552.


16

- 11. 3-Cl-5-OHC₆H₃CO₂H
WO 2002000633 and WO 2002044145.
- 12. 2-Cl-5-OHC₆H₃CO₂H
WO 9745400.
- 13. 5-I-2-OHC₆H₃CO₂H and 3-I, 2-OHC₆H₃CO₂H
Z. Chem. (1976), 16(8), 319-320.
- 14. 4-I-2-OHC₆H₃CO₂H
Journal of Chemical Research, Synopses (1994), (11), 405.
- 15. 6-I-2-OHC₆H₃CO₂H
- 10 U.S. Pat. No. 4,93,2999.
- 16. 2-I-3-OHC₆H₃CO₂H and 4-I-3-OHC₆H₃CO₂H
WO 9912928.
- 17. 5-I-3-OHC₆H₃CO₂H
J. Med. Chem. (1973), 16(6), 684-7.
- 15 18. 2-I-4-OHC₆H₃CO₂H
Collection of Czechoslovak Chemical Communications, (1991), 56(2), 459-77.
- 19. 3-I-4-OHC₆H₃CO₂,
J.O.C. (1990), 55(18), 5287-91.
- 20 The compound of formula XXXV, where R¹ is H and R³ is alkoxy having from 1 to 3 carbon atoms, i.e. compounds of formula:

Reaction Scheme 7




The compound of formula XXXV where R¹ is H and R³ is halo, i.e. compounds of formula:



are either commercially available or can be prepared according to the methods described in the literature as follows:

1. 3-Br or F-2-OHC₆H₃CO₂H
Canadian Journal of Chemistry (2001), 79(11) 1541-1545.
2. 4-Br-2-OHC₆H₃CO₂H
WO 9916747 or JP 04154773.
3. 2-Br-6-OHC₆H₃CO₂H
JP 47039101.
4. 2-Br-3-OHC₆H₃CO₂H
WO 9628423.
5. 4-Br-3-OHC₆H₃CO₂H
WO 2001002388.
6. 3-Br-5-OHC₆H₃CO₂H
Journal of Labelled Compounds and Radiopharmaceuticals (1992), 31 (3), 175-82.
7. 2-Br-5-OHC₆H₃CO₂H and 3-Cl-4-OHC₆H₃CO₂H
WO 9405153 and U.S. Pat. No. 5,519,133.
8. 2-Br-4-OHC₆H₃CO₂H and 3-Br-4-OHC₆H₃CO₂H
WO 20022018323
9. 2-Cl-6-OHC₆H₃CO₂H
JP 06293700
10. 2-Cl-3-OHC₆H₃CO₂H
Proceedings of the Indiana Academy of Science (1983), Volume date 1982, 92, 145-51.



can be synthesized via the reaction of scheme 8.

In the reaction of Scheme 8, R¹ and R³ are as above, and R⁴ is alkyl group having from 1 to 2 carbon atoms.

- 35 The compound of formula XXXVI can be converted to the compound of formula XXXVII by reducing the aldehyde to primary alcohol. In carrying out this reaction, it is preferred but not limited to use sodium borohydride as the reducing reagent. Any of the conditions suitable in such reduction reactions can be utilized to carry out the reaction of step (c').

The compound of formula XXXVII can be converted to the compound of formula XXXVIII via reaction of step (d') by protecting 1-3 Diols by using 1,1,3,3-Tetraisopropylsiloxane. The suitable conditions for this protecting group can be described in the Protecting Groups in Organic Synthesis by T. Greene.

- 45 50 The compound of formula XXXVIII can be converted to the compound of formula XXXIX via reaction of step (e') by protecting the phenol group using benzyl bromide. The suitable conditions for this protecting group can be described in the Protecting Groups in Organic Synthesis by T. Greene.

The compound of formula XXXIX can be converted to the compound of formula XL by deprotection using tetrabutylammonium fluoride via reaction of step (f). The suitable conditions for the deprotection can be described in the Protecting Groups in Organic Synthesis by T. Greene.

- 55 60 The compound of formula XL can be converted to compound of formula XLI via reaction of step (g') by oxidation. Any conventional oxidizing group that converts primary alcohol to an acid for example chromium oxide and the like can be utilized to carry out the reaction of step (g').

The compound of formula XLI can be converted to the compound of formula XLII by esterification of compound of formula XLI with methanol or ethanol. The reaction can be carried out either by using catalysts for example H₂SO₄, TsOH and the like or by using dehydrating agents for example

US 7,514,555 B2

17

dicyclohexylcarbodiimide and the like. Any of the conditions conventional in such esterification reactions can be utilized to carry out the reaction of step (h').


The compound of formula XLII can be converted to the compound of formula XLIII by etherifying or alkylating the compound of formula XLII with methyl halide or ethyl halide or propyl halide by using suitable base for example potassium carbonate, sodium hydride and the like. The reaction is carried out in conventional solvents, such as tetrahydrofuran, dimethylformamide. The reaction is generally carried out at temperatures of from 0° C. to 40° C. Any of the conditions suitable in such alkylation reactions can be utilized to carry out the reaction of step (i').

The compound of formula XLIII can be converted to the compound of formula XLIV via reaction of step (j') by deprotection of ester and benzyl groups. The suitable deprotecting conditions can be described in the Protecting Groups in Organic Synthesis by T. Greene.

18

1. 2-OMe-4-OHC₆H₃CO₂H
U.S. 2001034343 or WO 9725992.
2. 5-OMe-3-OHC₆H₃CO₂H
J.O.C (2001), 66(23), 7883-88.
3. 2-OMe-5-OHC₆H₃CO₂H
U.S. Pat. No. 6,194,406 (Page 96) and Journal of the American Chemical Society (1985), 107(8), 2571-3.
4. 3-OEt-5-OHC₆H₃CO₂H
Taiwan Kexue (1996), 49(1), 51-56.
5. 4-OEt-3-OHC₆H₃CO₂H
WO 9626176
6. 2-OEt-4-OHC₆H₃CO₂H
Takeda Kenkyusho Nempo (1965), 24,221-8.
JP 07070025.
7. 3-OEt-4-OHC₆H₃CO₂H
WO 9626176.
8. 3-OPr-2-OHC₆H₃CO₂H
JP 07206658, DE 2749518.


Reaction Scheme 8



The compound of formula XXXV, where R¹ is H and R³ is alkoxy having from 1 to 3 carbon atoms, i.e. compounds of formula:

- 55 9. 4-OPr-2-OHC₆H₃CO₂H
Farmacia (Bucharest) (1970), 18(8), 461-6.
JP 08119959.
10. 2-OPr-5-OHC₆H₃CO₂H and 2-OEt-5-OHC₆H₃CO₂H
Adapt synthesis from U.S. Pat. No. 6,194,406 (Page 96) by using propyl iodide and ethyl iodide.
- 60 11. 4-OPr-3-OHC₆H₃CO₂H
Adapt synthesis from WO 9626176
12. 2-OPr-4-OHC₆H₃CO₂H
Adapt synthesis from Takeda Kenkyusho Nempo (1965), 24,221-8 by using propyl halide.
- 65 13. 4-OEt-3-OHC₆H₃CO₂H Biomedical Mass Spectrometry (1985), 12(4), 163-9.

are either commercially available or can be prepared according to the methods described in the literature as follows:




US 7,514,555 B2

19

14. 3-OPr-5-OHC₆H₃CO₂H

Adapt synthesis from Taiwan Kexue (1996), 49(1), 51-56 by using propyl halide.

The compound of formula XXXV, where R¹ is H and R³ is an alkyl having from 1 to 3 carbon atoms, i.e. compounds of formula:



are either commercially available or can be prepared according to the methods described in the literature as follows:

1. 5-Me-3-OHC₆H₃CO₂H and 2-Me-5-OHC₆H₃CO₂H WO 9619437. J.O.C. 2001, 66, 7883-88.
2. 2-Me-4-OHC₆H₃CO₂H WO 8503701.
3. 3-Et-2-OHC₆H₃CO₂H and 5-Et-2-OHC₆H₃CO₂H J. Med. Chem. (1971), 14(3), 265.
4. 4-Et-2-OHC₆H₃CO₂H Yaxue Xuebao (1998), 33(1), 67-71.
5. 2-Et-6-OHC₆H₃CO₂H and 2-n-Pr-6-OHC₆H₃CO₂H J. Chem. Soc., Perkin Trans 1 (1979), (8), 2069-78.
6. 2-Et-3-OHC₆H₃CO₂H JP 10087489 and WO 9628423.
7. 4-Et-3-OHC₆H₃CO₂H J.O.C. 2001, 66, 7883-88. WO 9504046.
8. 2-Et-5-OHC₆H₃CO₂H J.A.C.S (1974), 96(7), 2121-9.
9. 2-Et-4-OHC₆H₃CO₂H and 3-Et-4-OHC₆H₃CO₂H JP 04282345.
10. 3-n-Pr-2-OHC₆H₃CO₂H J.O.C (1991), 56(14), 4525-29.
11. 4-n-Pr-2-OHC₆H₃CO₂H EP 279630.
12. 5-n-Pr-2-OHC₆H₃CO₂H J. Med. Chem (1981), 24(10), 1245-49
13. 2-n-Pr-3-OHC₆H₃CO₂H WO 9509843 and WO 9628423.
14. 4-n-Pr-3-OHC₆H₃CO₂H WO 9504046.
15. 2-n-Pr-5-OHC₆H₃CO₂H

Synthesis can be adapted from J.A.C.S (1974), 96(7), 2121-9 by using ethyl alpha formylvalerate.

16. 3-n-Pr-4-OHC₆H₃CO₂H Polymer (1991), 32(11) 2096-105.

17. 2-n-Pr-4-OHC₆H₃CO₂H


3-Propylphenol can be methylated to 3-Propylanisole, which was then formylated to 4-Methoxy-3-benzaldehyde. The aldehyde can be oxidized by Jone's reagent to give corresponding acid and deprotection of methyl group by BBr₃ will give the title compound.

18. 1. 3-Et-5-OHC₆H₃CO₂H and 3-Pr-n-5-OHC₆H₃CO₂H

Adapt synthesis from J.O.C. 2001, 66, 7883-88 by using 2-Ethylacrolein and 2-Propylacrolein.

The compound of formula XXI where R³ is hydrogen, halo, alkoxy having from 1 to 3 carbon atoms or alkyl having from 1 to 3 carbon atoms, i.e. compounds of formula:

20



10

can be prepared via reaction of scheme 9.

In the reaction scheme of Scheme 9, R⁴ is alkyl group having from 1 to 2 carbon atoms, and P is a protecting group.

15 The compound of formula XLV can be converted to the compound of formula XLVI via the reaction of step (k') by protecting the hydroxy group and then deprotecting the ester group by utilizing suitable protecting and deprotecting groups such as those described in Protecting Groups in Organic Synthesis by T. Greene.


20 The compound of formula XLVI can be converted to the compound of formula XLVII via reaction of step (l') by reducing acid group to alcohol group. The reaction can be carried out utilizing a conventional reducing agent for example alkali metal hydride such as lithium aluminum hydride. The reaction can be carried out in a suitable solvent, such as tetrahydrofuran. Any of the conditions conventional in such reduction reactions can be utilized to carry out the reaction of step (l').

25 The compound of formula XLVII can be converted to the compound of formula XLVIII via reaction of step (m') by oxidation of alcohol to the aldehyde. The reaction can be carried out utilizing a suitable oxidizing agent for example pyridinium chlorochromate, or dimethyl sulfoxide activated by 2,4,6-trichloro[1,3,5]-triazine (cyanuric chloride, TCT) under Swern oxidation conditions (J.O.C. 2001, 66, 7907-7909) and the like. Any of the conditions conventional in such oxidation reactions can be utilized to carry out the reaction of step (m').

30 In the compound of formula XLVIII, the hydroxy group can be deprotected via reaction of step (n') by suitable deprotecting reagents such as those described in Protecting Groups in Organic Synthesis by T. Greene to give the compound of formula XXI.

45


Reaction Scheme 9




(m')

US 7,514,555 B2

21



The compound of formula XLV where R^4 is alkyl group having from 1 to 2 carbon atoms and R^3 is halo, alkoxy having from 1 to 3 carbon atoms or alkyl having from 1 to 3 carbon atoms, i.e. compounds of formula:




can be prepared via reaction of scheme 10.

In the reaction of Scheme 10, R^1 is H. R^3 and R^4 are as above.

The compound of formula XXXV can be converted to the compound of formula XLV via reaction of step (o') by esterification of compound of formula XXXV with methanol or ethanol. The reaction can be carried out either by using catalysts for example H_2SO_4 , $TsOH$ and the like or by using dehydrating agents for example dicyclohexylcarbodiimide and the like. Any of the conditions conventional in such esterification reactions can be utilized to carry out the reaction of step (o').

Reaction Scheme 10



Use in Methods of Treatment

This invention provides a method for treating a mammalian subject with a condition selected from the group consisting of insulin resistance syndrome and diabetes (both primary essential diabetes such as Type I Diabetes or Type II Diabetes and secondary nonessential diabetes), comprising administering to the subject an amount of a biologically active agent as described herein effective to treat the condition. In accordance with the method of this invention a symptom of diabetes or the chance of developing a symptom of diabetes, such as atherosclerosis, obesity, hypertension, hyperlipidemia, fatty liver disease, nephropathy, neuropathy, retinopathy, foot ulceration and cataracts, each such symptom being associated with diabetes, can be reduced. This invention also provides a method for treating hyperlipidemia comprising administering to the subject an amount of a biologically active agent as described herein effective to treat the condition. As shown in the Examples, compounds reduce serum triglycerides and free fatty acids in hyperlipidemic animals. This invention also

22

provides a method for treating cachexia comprising administering to the subject an amount of a biologically active agent as described herein effective to treat the cachexia. This invention also provides a method for treating obesity comprising administering to the subject an amount of a biologically active agent as described herein effective to treat the condition. This invention also provides a method for treating a condition selected from atherosclerosis or arteriosclerosis comprising administering to the subject an amount of a biologically active agent as described herein effective to treat the condition. The active agents of this invention are effective to treat hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis or arteriosclerosis whether or not the subject has diabetes or insulin resistance syndrome. The agent can be administered by any conventional route of systemic administration. Preferably the agent is administered orally. Accordingly, it is preferred for the medicament to be formulated for oral administration. Other routes of administration that can be used in accordance with this invention include rectally, parenterally, by injection (e.g. intravenous, subcutaneous, intramuscular or intraperitoneal injection), or nasally.

Further embodiments of each of the uses and methods of treatment of this invention comprise administering any one of the embodiments of the biologically active agents described above. In the interest of avoiding unnecessary redundancy, each such agent and group of agents is not being repeated, but they are incorporated into this description of uses and methods of treatment as if they were repeated.

Many of the diseases or disorders that are addressed by the compounds of the invention fall into two broad categories: Insulin resistance syndromes and consequences of chronic hyperglycemia. Dysregulation of fuel metabolism, especially insulin resistance, which can occur in the absence of diabetes (persistent hyperglycemia) per se, is associated with a variety of symptoms, including hyperlipidemia, atherosclerosis, obesity, essential hypertension, fatty liver disease (NASH; non-alcoholic steatohepatitis), and, especially in the context of cancer or systemic inflammatory disease, cachexia. Cachexia can also occur in the context of Type I Diabetes or late-stage Type II Diabetes. By improving tissue fuel metabolism, active agents of the invention are useful for preventing or ameliorating diseases and symptoms associated with insulin resistance, as is demonstrated in animals in the Examples. While a cluster of signs and symptoms associated with insulin resistance may coexist in an individual patient, it many cases only one symptom may dominate, due to individual differences in vulnerability of the many physiological systems affected by insulin resistance. Nonetheless, since insulin resistance is a major contributor to many disease conditions, drugs which address this cellular and molecular defect are useful for prevention or amelioration of virtually any symptom in any organ system that may be due to, or exacerbated by, insulin resistance.

When insulin resistance and concurrent inadequate insulin production by pancreatic islets are sufficiently severe, chronic hyperglycemia occurs, defining the onset of Type II diabetes mellitus (NIDDM). In addition to the metabolic disorders related to insulin resistance indicated above, disease symptoms secondary to hyperglycemia also occur in patients with NIDDM. These include nephropathy, peripheral neuropathy, retinopathy, microvascular disease, ulceration of the extremities, and consequences of nonenzymatic glycosylation of proteins, e.g. damage to collagen and other connective tissues. Attenuation of hyperglycemia reduces the rate of onset and severity of these consequences of diabetes. Because, as is demonstrated in the Examples, active agents and compositions of the invention help to reduce hyperglycemia in diabe-

US 7,514,555 B2

23

tes, they are useful for prevention and amelioration of complications of chronic hyperglycemia.

Both human and non-human mammalian subjects can be treated in accordance with the treatment method of this invention. The optimal dose of a particular active agent of the invention for a particular subject can be determined in the clinical setting by a skilled clinician. In the case of oral administration to a human for treatment of disorders related to insulin resistance, diabetes, hyperlipidemia, fatty liver disease, cachexia or obesity the agent is generally administered in a daily dose of from 1 mg to 400 mg, administered once or twice per day. In the case of oral administration to a mouse the agent is generally administered in a daily dose from 1 to 300 mg of the agent per kilogram of body weight. Active agents of the invention are used as monotherapy in diabetes or insulin resistance syndrome, or in combination with one or more other drugs with utility in these types of diseases, e.g. insulin releasing agents, prandial insulin releasers, biguanides, or insulin itself. Such additional drugs are administered in accord with standard clinical practice. In some cases, agents of the invention will improve the efficacy of other classes of drugs, permitting lower (and therefore less toxic) doses of such agents to be administered to patients with satisfactory therapeutic results. Established safe and effective dose ranges in humans for representative compounds are: metformin 500 to 2550 mg/day; glyburide 1.25 to 20 mg/day; GLUCOVANCE (combined formulation of metformin and glyburide) 1.25 to 20 mg/day glyburide and 250 to 2000 mg/day metformin; atorvastatin 10 to 80 mg/day; lovastatin 10 to 80 mg/day; pravastatin 10 to 40 mg/day; and simvastatin 5-80 mg/day; clofibrate 2000 mg/day; gemfibrozil 1200 to 2400 mg/day; rosiglitazone 4 to 8 mg/day; pioglitazone 15 to 45 mg/day; acarbose 75-300 mg/day; repaglinide 0.5 to 16 mg/day.

Type I Diabetes Mellitus: A patient with Type I diabetes manages their disease primarily by self-administration of one to several doses of insulin per day, with frequent monitoring blood glucose to permit appropriate adjustment of the dose and timing of insulin administration. Chronic hyperglycemia leads to complications such as nephropathy, neuropathy, retinopathy, foot ulceration, and early mortality; hypoglycemia due to excessive insulin dosing can cause cognitive dysfunction or unconsciousness. A patient with Type I diabetes is treated with 1 to 400 mg/day of an active agent of this invention, in tablet or capsule form either as a single or a divided dose. The anticipated effect will be a reduction in the dose or frequency of administration of insulin required to maintain blood glucose in a satisfactory range, and a reduced incidence and severity of hypoglycemic episodes. Clinical outcome is monitored by measurement of blood glucose and glycosylated hemoglobin (an index of adequacy of glycemic control integrated over a period of several months), as well as by reduced incidence and severity of typical complications of diabetes. A biologically active agent of this invention can be administered in conjunction with islet transplantation to help maintain the anti-diabetic efficacy of the islet transplant.

Type II Diabetes Mellitus: A typical patient with Type II diabetes (NIDDM) manages their disease by programs of diet and exercise as well as by taking medications such as metformin, glyburide, repaglinide, rosiglitazone, or acarbose, all of which provide some improvement in glycemic control in some patients, but none of which are free of side effects or eventual treatment failure due to disease progression. Islet failure occurs over time in patients with NIDDM, necessitating insulin injections in a large fraction of patients. It is anticipated that daily treatment with an active agent of the invention (with or without additional classes of antidiabetic

24

medication) will improve glycemic control, reduce the rate of islet failure, and reduce the incidence and severity of typical symptoms of diabetes. In addition, active agents of the invention will reduce elevated serum triglycerides and fatty acids, thereby reducing the risk of cardiovascular disease, a major cause of death of diabetic patients. As is the case for all other therapeutic agents for diabetes, dose optimization is done in individual patients according to need, clinical effect, and susceptibility to side effects.

Hyperlipidemia: Elevated triglyceride and free fatty acid levels in blood affect a substantial fraction of the population and are an important risk factor for atherosclerosis and myocardial infarction. Active agents of the invention are useful for reducing circulating triglycerides and free fatty acids in hyperlipidemic patients. Hyperlipidemic patients often also have elevated blood cholesterol levels, which also increase the risk of cardiovascular disease. Cholesterol-lowering drugs such as HMG-CoA reductase inhibitors ("statins") can be administered to hyperlipidemic patients in addition to agents of the invention, optionally incorporated into the same pharmaceutical composition.

Fatty Liver Disease: A substantial fraction of the population is affected by fatty liver disease, also known as nonalcoholic steatohepatitis (NASH); NASH is often associated with obesity and diabetes. Hepatic steatosis, the presence of droplets of triglycerides with hepatocytes, predisposes the liver to chronic inflammation (detected in biopsy samples as infiltration of inflammatory leukocytes), which can lead to fibrosis and cirrhosis. Fatty liver disease is generally detected by observation of elevated serum levels of liver-specific enzymes such as the transaminases ALT and AST, which serve as indices of hepatocyte injury, as well as by presentation of symptoms which include fatigue and pain in the region of the liver, though definitive diagnosis often requires a biopsy. The anticipated benefit is a reduction in liver inflammation and fat content, resulting in attenuation, halting, or reversal of the progression of NASH toward fibrosis and cirrhosis.

Pharmaceutical Compositions

This invention provides a pharmaceutical composition comprising a biologically active agent as described herein and a pharmaceutically acceptable carrier. Further embodiments of the pharmaceutical composition of this invention comprise any one of the embodiments of the biologically active agents described above. In the interest of avoiding unnecessary redundancy, each such agent and group of agents is not being repeated, but they are incorporated into this description of pharmaceutical compositions as if they were repeated.

Preferably the composition is adapted for oral administration, e.g. in the form of a tablet, coated tablet, dragee, hard or soft gelatin capsule, solution, emulsion or suspension. In general the oral composition will comprise from 1 mg to 400 mg of such agent. It is convenient for the subject to swallow one or two tablets, coated tablets, dragees, or gelatin capsules per day. However the composition can also be adapted for administration by any other conventional means of systemic administration including rectally, e.g. in the form of suppositories, parenterally, e.g. in the form of injection solutions, or nasally.

The biologically active compounds can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical compositions. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragees and hard gelatin capsules. Suitable

US 7,514,555 B2

25

carriers for soft gelatin capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like. Depending on the nature of the active ingredient no carriers are, however, usually required in the case of soft gelatin capsules, other than the soft gelatin itself. Suitable carriers for the production of solutions and syrups are, for example, water, polyols, glycerol, vegetable oils and the like. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semiliquid or liquid polyols and the like.


The pharmaceutical compositions can, moreover, contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, coating agents or antioxidants. They can also contain still other therapeutically valuable substances, particularly antidiabetic or hypolipidemic agents that act through mechanisms other than those underlying the effects of the compounds of the invention. Agents which can advantageously be combined with compounds of the invention in a single formulation include but are not limited to biguanides such as metformin, insulin releasing agents such as the sulfonylurea insulin releaser glyburide and other sulfonylurea insulin releasers, cholesterol-lowering drugs such as the "statin" HMG-CoA reductase inhibitors such as atorvastatin, lovastatin, pravastatin and simvastatin, PPAR-alpha agonists such as clofibrate and gemfibrozil, PPAR-gamma agonists such as thiazolidinediones (e.g. rosiglitazone and pioglitazone), alpha-glucosidase inhibitors such as acarbose (which inhibit starch digestion), and prandial insulin releasers such as repaglinide. The amounts of complementary agents combined with compounds of the invention in single formulations are in accord with the doses used in standard clinical practice. Established safe and effective dose ranges for certain representative compounds are set forth above.

The invention will be better understood by reference to the following examples which illustrate but do not limit the invention described herein.

CHEMICAL SYNTHESIS EXAMPLES

Example 1

4-(3-(2,6-Dimethylbenzyloxy)-phenyl)-4(R)-hydroxybutanoic acid



Step A: Preparation of 4-(3-(2,6-Dimethylbenzyloxy)-phenyl)-4(R)-hydroxybutanoic acid

To a stirred solution of 4-(3-(2,6-Dimethylbenzyloxy)phenyl)-4-oxobutyric acid (WO 02/100341, 3 g, 9.6 mmol) in methanol (64 ml) was added cerium chloride (3.55 g, 14.4 mmol). The reaction mixture was stirred for 10 minutes at room temperature, cooled to 0°C., and NaBH₄ (0.400 g, 10.6 mmol) was added. The stirring continued at 0°C. for 4 hours, and the reaction was quenched with few drops of 50% aque-

26

ous acetic acid. Water (60 ml) and chloroform (60 ml) were added, and the reaction mixture was extracted with chloroform (3×25 ml). The organic layer was washed with water (2×) and brine (2×). The combined organic layer was dried over Na₂SO₄, filtered, concentrated and purified by flash column chromatography using chloroform:methanol (95:5 spiked with acetic acid) to give the title compound as white solid.

¹H NMR (270 MHz, CDCl₃): 2.1 (q, 2H); 2.4 (s, 6H); 2.5 (t, 2H); 4.8 (t, 1H); 5.1 (s, 2H); 6.9-7.1 (m, 4H); 7.15-7.3 (m, 3H).

BIOLOGICAL ACTIVITY EXAMPLES

For all of the biological activity examples that follow, Compound CR was produced in accordance with chemical synthesis example 1.

Example 2

Antidiabetic Effects of Compound CR in db/db mice—4 Weeks

Db/db mice have a defect in leptin signaling, leading to hyperphagia, obesity and diabetes. Moreover, unlike ob/ob mice on a C57BL/6J background, db/db mice on a C57BLKs background undergo failure of their insulin-producing pancreatic islet cells, resulting in progression from hyperinsulinemia (associated with peripheral insulin resistance) to hypoinsulinemic diabetes.

Male obese (db/db homozygote) C57BL/Ksola mice approximately 8 weeks of age, were obtained from Jackson Labs (Bar Harbor, Me.) and randomly assigned into groups of 5-7 animals such that the body weights (40-45 g) and serum glucose levels (≥ 300 mg/dL in fed state) were similar between groups; male lean (db/+heterozygote) mice served as cohort controls. A minimum of 7 days was allowed for adaptation after arrival. All animals were maintained under controlled temperature (23°C.), relative humidity (50±5%) and light (7:00-19:00), and allowed free access to standard chow (Formulab Diet 5008, Quality Lab Products, Elkridge, Md.) and water.

Treatment cohorts were given daily oral doses of vehicle, Compound BI (100 mg/kg), or Compound CR (100 mg/kg) for 4 weeks. At the end of the treatment period 100 µl of venous blood was withdrawn in a heparinized capillary tube from the retro-orbital sinus for serum chemistry analysis.

After 4 weeks of daily oral dosing, both Compound BI and Compound CR elicited a significant reduction in blood glucose (Table I). Both compounds also reduced serum triglycerides and free fatty acids (Table II) versus vehicle-treated db/db mice.

TABLE I

Effect of Compounds BI and CR on serum glucose in db/db mice: Treatment for 4 weeks

| Groups | Glucose ± SEM mg/dL |
|---------------------|------------------------|
| Lean Control | 193 ± 11 |
| Vehicle (db/db) | 747 ± 19 |
| Cpd. BI - 100 mg/kg | 189 ± 25* |
| Cpd. CR - 100 mg/kg | 235 ± 49* |

*p < 0.05 significantly lower than in vehicle-treated mice

US 7,514,555 B2

27

TABLE II

Effect of Compounds BI and CR on serum triglycerides and free fatty acids in db/db mice: Treatment for 4 weeks

| Group | Triglycerides \pm SEM mg/dL | Free Fatty Acids \pm SEM μ M |
|---------|----------------------------------|---------------------------------------|
| Lean | 96.4 \pm 6.4 | 1637 \pm 105 |
| Vehicle | 621 \pm 54 | 2415 \pm 134 |
| Cpd. BI | 125 \pm 11* | 1387 \pm 101* |
| Cpd. CR | 182 \pm 29* | 1634 \pm 78* |

* = p < .05 significantly lower than vehicle-treated values

Example 3

Antidiabetic Effects of Compound CR in db/db Mice—2 Weeks

The same procedure as Example 2 was followed. After 2 weeks of daily oral dosing, both Compound BI and Compound CR elicited a significant reduction in blood glucose (Table III).

Both compounds markedly reduce triglycerides; however at 2 weeks BI and not CR caused a decrease in free fatty acids (Table IV) as described below. (Compound CR did result in a decrease in free fatty acids at 4 weeks as described above in Example 2.)

TABLE III

The effects of Compounds BI and CR in a db/db mouse model of type I diabetes

| Groups | Glucose mg/dL | Glucose (% of Control) |
|-------------------|-------------------|------------------------|
| Vehicle (Control) | 752.9 \pm 46.0 | 100 \pm 6 |
| BI - 100 mg/kg | 317.4 \pm 48.0* | 42 \pm 6* |
| CR - 100 mg/kg | 263.2 \pm 59.0* | 35 \pm 8 |

*p < 0.05 significantly different compared with vehicle-control

TABLE IV


Effect of Compounds BI and CR on plasma serum glucose, triglycerides, and free fatty acids in db/db mice

| Group | Glucose \pm SEM | Triglycerides \pm SEM | Free Fatty Acids \pm SEM |
|---------|-------------------|-------------------------|----------------------------|
| Lean | 212.6 \pm 15.3 | 96.4 \pm 6.4 | 1417.2 \pm 54.3 |
| Vehicle | 752.9 \pm 46.0 | 388.0 \pm 50.7 | 1245.9 \pm 71.5 |
| BI | 317.4 \pm 48.0 | 136.3 \pm 18.1 | 1070.3 \pm 96.4 |
| CR | 263.2 \pm 59.0 | 86.3 \pm 9.4 | 1326.3 \pm 124.2 |

What is claimed is:

1. A biologically active agent, wherein the agent is a compound of the formula:

Formula I



wherein

n is 1 or 2;
m is 0, 1, 2, 3 or 4;

5 q is 0 or 1;
t is 0 or 1;
R^2 is alkyl having from 1 to 3 carbon atoms;
R^3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms;
A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or
cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or
a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and
R^1 is hydrogen or alkyl having 1 or 2 carbon atoms, provided that when m is 0 or 1, R^1 is not hydrogen;
or when R^1 is hydrogen, a pharmaceutically acceptable salt of the compound, wherein the agent is substantially pure.
10 2. The biologically active agent of claim 1, wherein n is 1, q is 0; t is 0; R^3 is hydrogen; and
A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy.
15 3. The biologically active agent of claim 2, wherein wherein A is 2,6-dimethylphenyl.
4. The biologically active agent of claim 3, 4-(3-(2,6-Dimethylbenzyloxy)-phenyl)-4-hydroxybutanoic acid.
25 5. A biologically active agent, wherein the agent is a compound of the formula:
30
35
40
45
50
55
60
65
70
75
80
85
90
95
Formula I

wherein
n is 1 or 2;
m is 0, 1, 2, 3 or 4;
q is 0 or 1;
t is 0 or 1;
R^2 is alkyl having from 1 to 3 carbon atoms;
R^3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms;
A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or
cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or
a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and
R^1 is hydrogen or alkyl having 1 or 2 carbon atoms, provided that when m is 0 or 1, R^1 is not hydrogen;

US 7,514,555 B2

29

or when R¹ is hydrogen, a pharmaceutically acceptable salt of the compound, wherein the agent is present in a mammal other than a mouse.

6. The biologically active agent of claim 5, wherein n is 1; q is 0; t is 0; R³ is hydrogen; and

A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy.


7. The biologically active agent of claim 6, wherein A is 2,6-dimethylphenyl.

8. The biologically active agent of claim 7, 4-(3-(2,6-Dimethylbenzyloxy)-phenyl)-4-hydroxybutanoic acid.

9. The biologically active agent of claim 8, wherein the mammal is a human.

10. The biologically active agent of claim 5, wherein the mammal is a human.

11. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and from one milligram to four hundred milligrams of a biologically active agent, wherein the agent is a compound of the formula:



wherein

n is 1 or 2;

m is 0, 1, 2, 3 or 4;

q is 0 or 1;

t is 0 or 1;

R² is alkyl having from 1 to 3 carbon atoms;

R³ is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms;

A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or

cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or

a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and

R¹ is hydrogen or alkyl having 1 or 2 carbon atoms, provided that when m is 0 or 1, R¹ is not hydrogen; or when R¹ is hydrogen, a pharmaceutically acceptable salt of the compound.

12. The pharmaceutical composition of claim 11, wherein n is 1; q is 0; t is 0; R³ is hydrogen; and

A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy.

13. The pharmaceutical composition of claim 12, wherein A is 2,6-dimethylphenyl.


14. The pharmaceutical composition of claim 13, wherein the biologically active agent is 4-(3-(2,6-Dimethylbenzyloxy)-phenyl)-4-hydroxybutanoic acid.

30

15. The pharmaceutical composition of claim 11 in oral dosage form.

16. A method for treating a mammalian subject with a condition selected from the group consisting of insulin resistance syndrome, and Type II Diabetes, comprising administering to the subject an amount of a biologically active agent, wherein the agent is a compound of the formula:

Formula I



wherein

20 n is 1 or 2;

m is 0, 1, 2, 3 or 4;

q is 0 or 1;

t is 0 or 1;

R² is alkyl having 1 to 3 carbon atoms;

25 R³ is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms;

A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or

cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or

25 a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and

R¹ is hydrogen or alkyl having 1 or 2 carbon atoms, provided that when m is 0 or 1, R¹ is not hydrogen; or when R¹ is hydrogen, a pharmaceutically acceptable salt of the compound.

17. The method of claim 16, wherein n is 1; q is 0; t is 0; R³ is hydrogen; and

A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy.

18. The method of claim 17, wherein A is 2,6-dimethylphenyl.

19. The method of claim 18, wherein the biologically active agent is 4-(3-(2,6-Dimethylbenzyloxy)-phenyl)-4-hydroxybutanoic acid.

20. The method of any one of claims 16 to 19, wherein the subject is a human.

21. The method of claim 20, wherein the agent is administered orally in an amount from one milligram to four hundred milligrams per day.

22. The method of claim 16, wherein the treatment reduces a symptom of diabetes or the chances of developing a symptom of diabetes, wherein the symptom is selected from the group consisting of: atherosclerosis, obesity, hypertension, hyperlipidemia, fatty liver disease, nephropathy, neuropathy, retinopathy, foot ulceration and cataracts, associated with diabetes.

* * * * *

Exhibit B

Civil Case No. 1:09-cv-01866-PLF

580 F.Supp.2d 138
WYETH, et al. Plaintiffs,

v.

**Jon W. DUDAS, Under Secretary of Commerce for Intellectual Property and Director of U.S.
Patent and Trademark Office, Defendant.**
Civil Action No. 07-1492 (JR).
United States District Court, District of Columbia.
September 30, 2008.

David O. Bickart, Kaye Scholer LLP,
Washington, DC, Patricia A. Carson, Kaye
Scholer LLP, New York, NY, for Plaintiffs.

Fred Elmore Haynes, U.S. Attorney's
Office, Washington, DC, for Defendant.

Page 139

MEMORANDUM OPINION

JAMES ROBERTSON, District Judge.

Plaintiffs here take issue with the interpretation that the United States Patent and Trademark Office (PTO) has imposed upon 35 U.S.C. § 154, the statute that prescribes patent terms. Section 154(a)(2) establishes a term of 20 years from the day on which a successful patent application is first filed. Because the clock begins to run on this filing date, and not on the day the patent is actually granted, some of the effective term of a patent is consumed by the time it takes to prosecute the application. To mitigate the damage that bureaucracy can do to inventors, the statute grants extensions of patent terms for certain specified kinds of PTO delay, 35 U.S.C. § 154(b)(1)(A), and, regardless of the reason, whenever the patent prosecution takes more than three years. 35 U.S.C. § 154(b)(1)(B). Recognizing that the protection provided by these separate guarantees might overlap, Congress has forbidden double-counting: "To the extent that periods of delay attributable to grounds specified in paragraph (1) overlap, the period of any adjustment granted under this subsection shall not exceed the actual number of days the issuance of the patent was delayed." 35 U.S.C. § 154(b)(2)(A). Plaintiffs claim that the PTO has misconstrued or misapplied this provision, and that the PTO is denying them a

portion of the term Congress has provided for the protection of their intellectual property rights.

Statutory Scheme

Until 1994, patent terms were 17 years from the date of issuance. See 35 U.S.C. § 154 (1992) ("Every patent shall contain ... a grant ... for the term of seventeen years ... of the right to exclude others from making, using, or selling the invention throughout the United States...."). In 1994, in order to comply with treaty obligations under the General Agreement on Tariffs and Trade (GATT), the statute was amended to provide a 20-year term from the date on which the application is first filed. See Pub.L. No. 103-465, § 532, 108 Stat. 4809, 4984 (1994). In 1999, concerned that extended prosecution delays could deny inventors substantial portions of their effective patent terms under the new regime, Congress enacted the American Inventors Protection Act, a portion of which—referred to as the Patent Term Guarantee Act of 1999—provided for the adjustments that are at issue in this case. Pub.L. No. 106-113, §§ 4401-4402, 113 Stat. 1501, 1501A-557 (1999).

As currently codified, 35 U.S.C. § 154(b) provides three guarantees of patent term, two of which are at issue here. The first is found in subsection (b)(1)(A), the "[g]uarantee of prompt Patent and Trademark Office response." It provides a one-day extension of patent term for every day that issuance of a patent is delayed by a failure of the PTO to comply with various enumerated statutory deadlines: fourteen months for a first office action; four months to respond to a reply; four months to issue a patent after the fee is paid; and the like. See 35 U.S.C. §

154(b)(1)(A)(i)-(iv). Periods of delay that fit under this provision are called "A delays" or "A periods." The second provision is the "[g]uarantee of no more than 3-year application pendency." Under this provision, a one-day term extension is granted for every day greater than three years after the filing date that it takes for the patent to issue, regardless of whether the delay is the fault of the PTO.¹ See 35 U.S.C.

Page 140

§ 154(b)(1)(B). The period that begins after the three-year window has closed is referred to as the "B delay" or the "B period." ("C delays," delays resulting from interferences, secrecy orders, and appeals, are similarly treated but were not involved in the patent applications underlying this suit.)

The extensions granted for A, B, and C delays are subject to the following limitation:

(A) In general.—To the extent that periods of delay attributable to grounds specified in paragraph (1) overlap, the period of any adjustment granted under this subsection shall not exceed the actual number of days the issuance of the patent was delayed.

35 U.S.C. § 154(b)(2)(A). This provision is manifestly intended to prevent double-counting of periods of delay, but understanding that intent does not answer the question of what is double-counting and what is not. Proper interpretation of this proscription against windfall extensions requires an assessment of what it means for "periods of delay" to "overlap."

The PTO, pursuant to its power under 35 U.S.C. § 154(b)(3)(A) to "prescribe regulations establishing procedures for the application for and determination of patent term adjustments," has issued final rules and an "explanation" of the rules, setting forth its authoritative construction of the double-counting provision. The rules that the PTO has promulgated essentially parrot the statutory text, see 37 C.F.R. § 1.703(f), and so the real interpretive act is found in something the PTO calls its Explanation of 37 CFR 1.703(f) and of the United States Patent and

Fastcase

Trademark Office Interpretation of 35 U.S.C. § 154(b)(2)(A), which was published on June 21, 2004, at 69 Fed.Reg. 34238. Here, the PTO "explained" that:

the Office has consistently taken the position that if an application is entitled to an adjustment under the three-year pendency provision of 35 U.S.C. § 154(b)(1)(B), the entire period during which the application was pending before the Office (except for periods excluded under 35 U.S.C. § 154(b)(1)(B)(i)-(iii)), and not just the period beginning three years after the actual filing date of the application, is the relevant period under 35 U.S.C. § 154(b)(1)(B) in determining whether periods of delay "overlap" under 35 U.S.C. 154(b)(2)(A).

69 Fed.Reg. 34238 (2004) (emphasis added). In short, the PTO's view is that any administrative delay under § 154(b)(1)(A) overlaps any 3-year maximum pendency delay under § 154(b)(1)(B): the applicant gets credit for "A delay" or for "B delay," whichever is larger, but never A + B.

In the plaintiffs' submission, this interpretation does not square with the language of the statute. They argue that the "A period" and "B period" overlap only if they occur on the same calendar day or days. Consider this example, proffered by plaintiff: A patent application is filed on 1/1/02. The patent issues on 1/1/08, six years later. In that six-year period are two "A periods," each one year long: (1) the 14-month deadline for first office action is 3/1/03, but the first office action does not occur until 3/1/04, one year late; (2) the 4-month deadline for patent issuance after payment of the issuance fee is 1/1/07, but the patent does not issue until 1/1/08, another year of delay attributable to the PTO. According to plaintiff, the "B period" begins running on 1/1/05, three years after the patent application was filed, and ends three years later, with the issuance of the patent on 1/1/08. In this

Page 141

example, then, the first "A period" does not overlap the "B period," because it occurs in

2003-04, not in 2005-07. The second "A period," which covers 365 of the same days covered by the "B period," does overlap. Thus, in plaintiff's submission, this patent holder is entitled to four years of adjustment (one year of "A period" delay + three years of "B period" delay). But in the PTO's view, since "the entire period during which the application was pending before the office" is considered to be "B period" for purposes of identifying "overlap," the patent holder gets only three years of adjustment.

Chevron Deference

We must first decide whether the PTO's interpretation is entitled to deference under *Chevron v. NRDC*, 467 U.S. 837, 104 S.Ct. 2778, 81 L.Ed.2d 694 (1984). No, the plaintiffs argue, because, under the Supreme Court's holdings in *Gonzales v. Oregon*, 546 U.S. 243, 126 S.Ct. 904, 163 L.Ed.2d 748 (2006), and *United States v. Mead Corp.*, 533 U.S. 218, 121 S.Ct. 2164, 150 L.Ed.2d 292 (2001), Congress has not "delegated authority to the agency generally to make rules carrying the force of law," and in any case the interpretation at issue here was not promulgated pursuant to any such authority. See *Gonzales*, 546 U.S. at 255-56, 126 S.Ct. 904, citing *Mead*, 533 U.S. at 226-27, 121 S.Ct. 2164. Since at least 1996, the Federal Circuit has held that the PTO is not afforded Chevron deference because it does not have the authority to issue substantive rules, only procedural regulations regarding the conduct of proceedings before the agency. See *Merck & Co. v. Kessler*, 80 F.3d 1543, 1549-50 (Fed.Cir.1996).

Here, as in *Merck*, the authority of the PTO is limited to prescribing "regulations establishing procedures for the application for and determination of patent term adjustments under this subsection." 35 U.S.C. § 154(b)(3)(A) (emphasis added). Indeed, a comparison of this rulemaking authority with the authority conferred for a different purpose in the immediately preceding section of the statute makes it clear that the PTO's authority to interpret the overlap provision is quite limited. In 35 U.S.C. § 154(b)(2)(C)(iii) the PTO is

given the power to "prescribe regulations establishing the circumstances that constitute a failure of an applicant to engage in reasonable efforts to conclude processing or examination of an application" (emphasis added)—that is, the power to elaborate on the meaning of a particular statutory term. No such power is granted under § 154(b)(3)(A). Chevron deference does not apply to the interpretation at issue here.

Statutory Construction

Chevron would not save the PTO's interpretation, however, because it cannot be reconciled with the plain text of the statute. If the statutory text is not ambiguous enough to permit the construction that the agency urges, that construction fails at Chevron's "step one," without regard to whether it is a reasonable attempt to reach a result that Congress might have intended. See, e.g., *MCI v. AT & T*, 512 U.S. 218, 229, 114 S.Ct. 2223, 129 L.Ed.2d 182 (1994) ("[A]n agency's interpretation of a statute is not entitled to deference when it goes beyond the meaning that the statute can bear.").

The operative question under 35 U.S.C. § 154(b)(2)(A) is whether "periods of delay attributable to grounds specified in paragraph (1) overlap." The only way that periods of time can "overlap" is if they occur on the same day. If an "A delay" occurs on one calendar day and a "B delay" occurs on another, they do not overlap, and § 154(b)(2)(A) does not limit the extension to one day. Recognizing this,

Page 142

the PTO defends its interpretation as essentially running the "period of delay" under subsection (B) from the filing date of the patent application, such that a period of "B delay" always overlaps with any periods of "A delay" for the purposes of applying § 154(b)(2)(A).

The problem with the PTO's construction is that it considers the application delayed under § 154(b)(1)(B) during the period before it has been delayed. That construction cannot be squared with the language of § 154(b)(1)(B), which

applies "if the issue of an original patent is delayed due to the failure of the United States Patent and Trademark Office to issue a patent within 3 years." (Emphasis added.) "B delay" begins when the PTO has failed to issue a patent within three years, not before.

The PTO's interpretation appears to be driven by Congress's admonition that any term extension "not exceed the actual number of days the issuance of the patent was delayed," and by the PTO's view that "A delays" during the first three years of an applications' pendency inevitably lead to "B delays" in later years. Thus, as the PTO sees it, if plaintiffs' construction is adopted, one cause of delay will be counted twice: once because the PTO has failed to meet an administrative deadline, and again because that failure has pushed back the entire processing of the application into the "B period." Indeed, in the example set forth above, plaintiffs' calendar-day construction does result in a total effective patent term of 18 years under the (B) guarantee, so that—again from the PTO's viewpoint—the applicant is not "compensated" for the PTO's administrative delay, he is benefitted by it.

But if subsection (B) had been intended to guarantee a 17-year patent term and no more, it could easily have been written that way. It is true that the legislative context—as distinct from the legislative history—suggests that Congress may have intended to use subsection (B) to guarantee the 17-year term provided before GATT. But it chose to write a "[g]uarantee of no more than 3-year application pendency," 35 U.S.C. § 154(b)(1)(B), not merely a guarantee of 17 effective years of patent term, and do so using language separating that guarantee from a different promise of prompt administration in subsection (A). The PTO's efforts to prevent windfall extensions may be reasonable—they may even be consistent with Congress's intent—but its interpretation must square with Congress's words. If the outcome commanded by that text is an unintended result, the problem is for Congress to remedy, not the agency.

Notes:

1. Certain reasons for exceeding the three-year pendency period are excluded, see 35 U.S.C. § 154(b)(1)(B)(i)-(iii), as are periods attributable to the applicant's own delay. See 35 U.S.C. § 154(b)(2)(C).


Exhibit C

Civil Case No. 1:09-cv-01866-PLF



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov



Wellstat Management Company, LLC
LEGAL DEPARTMENT
930 CLOPPER ROAD
GAITHERSBURG MD 20878

In re Patent No. 7,514,555 :
Hodge et al. :
Application No. 10/531618 : DECISION ON
Issue Date: 04/07/2009 : REQUEST FOR RECONSIDERATION
Filing or 371(c) Date: 04/14/2005 : OF PATENT TERM ADJUSTMENT
Attorney Docket No. 18034-PCTUS :
:

This is a decision on the "REQUEST FOR RECONSIDERATION OF PATENT TERM ADJUSTMENT UNDER 37 CFR §1.705(d)," filed June 3, 2009, requesting that the patent term adjustment determination for the above-identified patent be changed from 82 days, to not less than 241 days. The application is properly treated under 37 CFR §1.705(d).

The request for reconsideration of patent term adjustment is **DISMISSED**.

On April 7, 2009, the above-identified application matured into US Patent No. 7,514,555 with a patent term adjustment of 82 days. This request for reconsideration of patent term adjustment was timely filed within two months of the issue date of the patent. See 37 CFR 1.705(d).

Patentees request recalculation of the patent term adjustment based on the decision in Wyeth v. Dudas, 580 F. Supp. 2d 138, 88 U.S.P.Q. 2d 1538 (D.D.C. 2008). Patentees assert that pursuant to Wyeth, the term of the patent is extended for the number of days that issuance of the patent was delayed by failures of the Office to promptly take certain actions (35 U.S.C. § 154(b)(1)(A) ("A delays"), and the term of the patent is extended for the number of days that the Office failed to issue a patent by the three-year anniversary of the date that the application for patent was first filed (35 U.S.C. § 154(b)(1)(B) ("B delays"). Patentees state that the Patent Term Adjustment is calculated by adding the "A delays" plus the "B delay," except to the extent that the periods of delay overlap 35 U.S.C. § 154(b)(2)(A)). Application for PTA at p.2. Patentees maintain that there is no overlap between the "A delays" and the "B delay" in this case. Therefore, Patentees

Patent No. 7,514,555 Application No. 10/531618

Page 2

that the period of adjustment is 517 days, which is the sum of 159 days of "A delays" and 358 days of "B delay."

The 358-day period is calculated based on the date the application commenced the national stage on April 14, 2005, and the patent having been issued on April 7, 2009, three years and 358 days later. Patentees assert that in addition to this 358-day period, they are entitled to a period of adjustment due to examination delay pursuant to 37 CFR 1.702(a) totalling 159 days. This 159-day period is the result of a period of delay of 146 days for the failure by the Office to mail at least one of a notification under 35 U.S.C. 132 not later than fourteen months after the date on which application was filed under 35 U.S.C. 111(a), pursuant to 37 CFR 1.702(a)(1), and a period of delay of 13 days for the failure by the Office to respond to a reply under 35 U.S.C. 132 not later than four months after the date on which the reply was filed, pursuant to 37 CFR 1.702(a)(2).

Under 37 CFR 1.703(f), patentees are entitled to a period of patent term adjustment equal to the period of delays based on the grounds set forth in 37 CFR 1.702 reduced by the period of time equal to the period of time during which patentees failed to engage in reasonable efforts to conclude prosecution pursuant to 37 CFR 1.704. In other words, patentees are entitled to the period of Office delay reduced by the period of applicant delay.

The Office agrees that as of the issuance of the patent on April 7, 2009, the application was pending three years and 358 days after its filing date. The Office agrees that the action detailed above was not taken within the specified time frame, and thus, the entry of a period of adjustment of 159 days is correct. At issue is whether patentees should accrue 358 days of patent term adjustment for the Office taking in excess of three years to issue the patent, as well as 159 days for Office failure to take a certain action within a specified time frame (or examination delay).

The Office contends that 159 days of examination delay overlap with the 358 days of delay in issuance of the patent. Patentee's calculation of the period of overlap is inconsistent with the Office's interpretation of this provision. 35 U.S.C. 154(b)(2)(A) limits the adjustment of patent term, as follows:

To the extent that the periods of delay attributable to grounds specified in paragraph (1) overlap, the period of any adjustment granted under this subsection shall not exceed the actual number of days the issuance of the patent was delayed.

Likewise, 35 CFR 1.703(f) provides that:

To the extent that periods of delay attributable to the grounds specified in § 1.702 overlap, the period of adjustment granted under this section shall not exceed the actual number of days the issuance of the patent was delayed.

As explained in *Explanation of 37 CFR 1.703(f) and of the United States Patent and Trademark Office Interpretation of 35 U.S.C. 154(b)(2)(A)*, 69 Fed. Reg. 34283 (June 21, 2004), the Office interprets 35 U.S.C. 154(b)(2)(A) as permitting either patent term adjustment under 35 U.S.C. 154(b)(1)(A)(i)-(iv), or patent term adjustment under 35 U.S.C. 154(b)(1)(B), but not as permitting patent term adjustment under both 35 U.S.C. 154(b)(1)(A)(i)-(iv) and 154(b)(1)(B). Accordingly, the Office implements the overlap provision as follows:

If an application is entitled to an adjustment under 35 U.S.C. 154(b)(1)(B), the entire period during which the application was pending (except for periods excluded under 35 U.S.C. 154(b)(1)(B)(i)-(iii)), and not just the period beginning three years after the actual filing date of the application, is the period of delay under 35 U.S.C. 154(b)(1)(B) in determining whether periods of delay overlap under 35 U.S.C. 154(b)(2)(A). Thus, any days of delay for Office issuance of the patent more than 3 years after the filing date of the application, which overlap with the days of patent term adjustment accorded prior to the issuance of the patent will not result in any additional patent term adjustment. See 35 U.S.C. 154(b)(1)(B), 35 U.S.C. 154(b)(2)(A), and 37 CFR § 1.703(f). See *Changes to Implement Patent Term Adjustment Under Twenty Year Term; Final Rule*, 65 Fed. Reg. 56366 (Sept. 18, 2000). See also *Revision of Patent Term Extension and Patent Term Adjustment Provisions; Final Rule*, 69 Fed. Reg. 21704 (April 22, 2004), 1282 Off. Gaz. Pat. Office 100 (May 18, 2004). See also *Explanation of 37 CFR 1.703(f) and of the United States Patent and Trademark Office Interpretation of 35 U.S.C. 154(b)(2)(A)*, 69 Fed. Reg. 34283 (June 21, 2004).

The current wording of § 1.703(f) was revised in response to the misinterpretation of this provision by a number of Patentees. The rule was slightly revised to more closely track the corresponding language of 35 U.S.C. 154(b)(2)(A). The relevant portion differs only to the extent that the statute refers back to provisions of the statute whereas the rule refers back to sections of the rule. This was not a substantive change to the rule nor did it reflect a change of the Office's interpretation of 35 U.S.C. 154(b)(2)(A). As stated in the *Explanation of 37 CFR 1.703(f) and of the United States Patent and Trademark Office Interpretation of 35 U.S.C. 154(b)(2)(A)*, the Office has consistently taken the position that if an application is entitled to an adjustment under the three-year pendency provision of 35 U.S.C. 154(b)(1)(B), the entire period during which the application was pending before the Office (except for periods excluded under 35 U.S.C. 154(b)(1)(B)(i)-(iii)), and not just the period beginning three years after the actual filing date of the application, is the relevant period under 35 U.S.C. 154(b)(1)(B) in determining whether periods of delay "overlap" under 35 U.S.C. 154(b)(2)(A).

This interpretation is consistent with the statute. Taken together the statute and rule provide that to the extent that periods of delay attributable to grounds specified in 35 U.S.C. 154(b)(1) and in corresponding § 1.702 overlap, the period of adjustment granted shall not exceed the actual number of days the issuance of the patent was delayed. The grounds specified in these sections cover the A) guarantee of prompt Patent and Trademark Office responses, B) guarantee of no more than 3-year application pendency, and C) guarantee or adjustments for delays due to

Patent No. 7,514,555 Application No. 10/531618

Page 4

interference, secrecy orders and appeals. A section by section analysis of 35 U.S.C. 154(b)(2)(A) specifically provides that:

Section 4402 imposes limitations on restoration of term. In general, pursuant to [35 U.S.C.] 154(b)(2)(A)-(C), total adjustments granted for restorations under [35 U.S.C.] 154](b)(1) are reduced as follows: (1) To the extent that there are multiple grounds for extending the term of a patent that may exist simultaneously (e.g., delay due to a secrecy order under [35 U.S.C.] 181 and administrative delay under [35 U.S.C.] 154(b)(1)(A)), the term should not be extended for each ground of delay but only for the actual number of days that the issuance of a patent was delayed; See 145 Cong. Rec. S14,718¹

As such, the period for over three-year pendency does not overlap only to the extent that the actual dates in the period beginning three years after the date on which the application was filed overlap with the actual dates in the periods for failure of the Office to take action within specified time frames. In other words, consideration of the overlap does not begin three years after the date the application commenced the national stage.

In this instance, the relevant period under 35 U.S.C. 154(b)(1)(B) in determining whether periods of delay "overlap" under 35 U.S.C. 154(b)(2)(A) is the entire period during which the application was pending before the Office, April 14, 2005, to the date the patent issued on April 7, 2009. Prior to the issuance of the patent, 159 days of patent term adjustment were accorded for the Office failing to respond within a specified time frame during the pendency of the application. All of the 159 days of Office delay overlap with the 358 days for Office delay in issuing the patent. During that time, the issuance of the patent was delayed by 358 days, not 159 days + 358 days. The Office took 14 months and 143 days to issue a first Office action, and four months and 13 days to respond to a reply under 35 U.S.C. 132. Otherwise, the Office took all actions set forth in 37 CFR 1.702(a) within the prescribed timeframes. Nonetheless, given the initial 159 days of Office delay and the time allowed within the time frames for processing and examination, the application issued three years and 358 days after its filing date. The Office did not delay 159 days and then an additional 358 days. Accordingly, 358 days of patent term adjustment was properly entered because the period of delay of 159 days attributable to grounds specified in § 1.702(a) overlaps with the adjustment of 358 days attributable to the delay in the issuance of the patent. Entry of both periods is not warranted.

Accordingly, at issuance, the Office entered 358 days of patent term adjustment.

In view thereof, no adjustment to the patent term will be made.

¹ The AIPA is title IV of the Intellectual Property and Communications Omnibus Reform Act of 1999 (S. 1948), which was incorporated and enacted as law as part of Pub. L. 106-113. The Conference Report for H.R. 3194, 106th Cong. 1st Sess. (1999), which resulted in Pub. L. 106-113, does not contain any discussion (other than the incorporated language) of S. 1948. A section-by-section analysis of S. 1948, however, was printed in the Congressional Record at the request of Senator Lott, See 145 Cong. Rec. S14,708-26 (1999)(daily ed. Nov. 17, 1999).

Patent No. 7,514,555 Application No. 10/531618

Page 5

The Office acknowledges submission of the \$200.00 fee set forth in 37 CFR 1.18(e). No additional fees are required.

Telephone inquiries specific to this matter should be directed to Attorney Derek Woods, at (571) 272-3232.



Alesia Brown
Senior Petitions Attorney
Office of Petitions
Office of the Deputy Commissioner
for Patent Examination Policy